| 产品详情 |
| Edit |   |
|---|
| Product Name | GSK 1838705 |
|---|
| Description | Potent insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) inhibitor (IC50 values are 1.6 and 2 nM, respectively). Also inhibits anaplastic lymphoma kinase (ALK) (IC50 = 0.5 nM). Displays > 800-fold selectivity for IR, IGFR1 and ALK over a panel of 44 kinases including JNK. Blocks proliferation of cancer cell lines in vitro, and causes complete regression of ALK-dependent tumors in vivo. Orally bioavailable. Purity 98%. MW (observed): 532.57 |
|---|
| Size | 50 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 2-[[2-[[1-[(Dimethylamino)ethanoyl]-5-(methyloxy)-2,3-dihydro-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide |
|---|
| Gene, Accession, CAS # | CAS: 1116235-97-2 |
|---|
| Catalog # | 5111/50 |
|---|
| Price | |
|---|
| Order / More Info | GSK 1838705 from TOCRIS BIOSCIENCE
|
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|